You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK)就漢利康及漢曲優與雅培(ABT.US)附屬訂巴西半獨家許可協議
阿思達克 05-24 18:00
復宏漢霖-B(02696.HK公佈,公司已與雅培(ABT.US)旗下Abbott Operations Uruguay 訂立一份產品許可協議,公司同意授予Abbott於巴西內及領域內對漢利康及漢曲優進行商業化的半獨家許可,以及作爲備用生產商或委託備用生產商生產許可產品的非獨家許可。 漢利康(利妥昔單抗注射液)是公司自主研發的利妥昔單抗,目前漢利康適應症覆蓋非霍奇金淋巴瘤,慢性淋巴細胞白血病(CLL),及類風溼關節炎(RA)。至於漢曲優(注射用曲妥珠單抗)是公司自主研發的曲妥珠單抗,目前漢曲優適應症覆蓋HER2陽性的早期乳腺癌,HER2陽性的轉移性乳腺癌,及HER2陽性的轉移性胃腺癌或胃食管交界處腺癌。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account